Physician profile
Chad E Lamendola
NPI 1285670265
$4,360.80
in general payments reported to CMS, 2019-2025
23 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $216 · 2021: $559 · 2022: $450 · 2023: $525 · 2024: $1,001 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $976.00 | 2019-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $767.63 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $566.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $311.98 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.82 | 2020-2025 | Xifaxan, Trulance |
| Abbvie INC. | $182.44 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.39 | 2019-2020 | |
| Pfizer INC. | $170.46 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $133.14 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $132.87 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $123.63 | 2021-2022 | |
| Exact Sciences Corporation | $102.56 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $87.10 | 2021 | |
| Bausch Health US, LLC | $72.37 | 2021-2023 | Wellbutrin, Aplenzin |
| Allergan, INC. | $71.50 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $56.17 | 2022 | |
| Shire North American Group INC | $47.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $43.31 | 2019-2021 | |
| Abbott Laboratories | $24.83 | 2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $20.95 | 2025 | Unithroid |
| Hikma Pharmaceuticals USA | $16.75 | 2024 | Ryaltris |
| Amgen INC. | $14.67 | 2021 | |
| Amarin Pharma, INC. | $14.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Lamendola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.